The Saudi Food and Drug Authority (SFDA) approves our treatment for #SickleCellDisease and #BetaThalassemia in the Kingdom of Saudi Arabia. Learn more: vrtx.com/?utm_source=co…

#Breaking The U.S. FDA approves our treatment for #BetaThalassemia. We are thrilled to see this approval provide a new option to eligible patients who have been waiting. Learn more: news.vrtx.com/news-releases/…

Today we’re excited to announce positive results from the Phase 3 studies of our investigational treatment for moderate-to-severe acute pain. Learn more: news.vrtx.com/news-releases/…

We are pleased to announce positive Phase 3 results from our investigational triple combination therapy for the treatment of certain mutations of cystic fibrosis. Learn more: news.vrtx.com/news-releases/…

Vertex Reports Fourth Quarter 2023 Financial Results. news.vrtx.com/news-releases/…

Today the Australian Therapeutic Goods Administration (TGA) approved the indication expansion of our fourth #CysticFibrosis (CF) medicine. This marks an important step towards our goal of treating all people with CF.

#Breaking The European Commission (EC) approves our treatment for #SickleCellDisease and #BetaThalassemia for the European Union. Learn more: vrtx.com/?utm_source=tw…

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansion of the first of our four #CysticFibrosis (CF) medicines. This marks an important step towards our goal of treating all people with CF.

On #RareDiseaseDay, our Boston office will be lit in pink, purple, blue and green to represent the 300 million people living with a #RareDisease. Join us in honoring this community and spreading awareness. #ShowYourStripes #ShareYourColours

At Vertex, we’re inspired by the patients and communities we seek to serve. We’re proud to light up our #Boston building green on #WorldKidneyDay to raise awareness of and show our support for those living with APOL1-mediated #KidneyDisease (AMKD). #NationalKidneyMonth

Moving to the clinic: U.S. FDA clears our Investigational New Drug application for the potential treatment of autosomal dominant polycystic kidney disease (ADPKD). Learn more: vrtx.com/?utm_source=tw…

Our investigational treatment for APOL1-mediated kidney disease (AMKD) will advance into the Phase 3 portion of our Phase 2/3 pivotal trial. Learn more: vrtx.com/?utm_source=tw…

We’re pleased to announce significant progress across our pain program. Learn more: news.vrtx.com/news-releases/…

Today the European Commission approved the label expansion of the first of our four #CysticFibrosis (CF) medicines. This marks an important step towards our goal of treating all people with CF.

News from #ECFS2024: We’ve announced #CFResearch data for our #CysticFibrosis medicines. Learn more: vrtx.com

We are excited to announce new data at the 2024 European Hematology Association Congress on our CRISPR/Cas9 gene-edited treatment, along with new health and economics outcomes research highlighting disease burdens. Learn more about our work: vrtx.com/?utm_source=tw…

We are pleased to share new data from our Phase 1/2 clinical trial for our investigational type 1 diabetes treatment at the 2024 @amdiabetesassn Scientific Sessions. Learn more: news.vrtx.com/news-releases/…

#Breaking: The U.S. FDA has accepted the application and granted Priority Review for our fifth investigational CFTR modulator #CysticFibrosis. Learn more: news.vrtx.com/press-releases…

Extended reimbursement agreement with the Ministry of Health in #Montegro. Since July 1 eligible children living with #CysticFibrosis ages 2 and older have broad access to one of our medicines.

We are excited to share that the FDA has accepted and granted priority review to the New Drug Application (NDA) submission for our investigational acute pain medicine. Learn more: news.vrtx.com/news-releases/…